Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

The following is a summary of “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis,” published in the November ...

In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay ...

However, authors caution there is little high-quality evidence. (HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid ...